We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sanofi Pasteur and Immune Design Collaborate on a Vaccine to Treat HSV

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sanofi Pasteur and Immune Design Collaborate on a Vaccine to Treat HSV"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Sanofi Pasteur and Immune Design Corp. have announced that they have entered into a broad collaboration for the development of a herpes simplex virus (HSV) immune therapy.

Sanofi Pasteur and Immune Design will each contribute product candidates to the collaboration: Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate.

The collaboration will explore the potential of various combinations of agents, including Immune Design’s GLAAS™ platform, with the goal to select the best potential immune therapy for patients.

“We intend to develop the best in class HSV therapeutic vaccine by pooling assets of Sanofi Pasteur and of Immune Design,” explained John Shiver, PhD, Senior VP for R&D, Sanofi Pasteur. “Given the challenges of vaccine development,” Shiver continued, “collaborations are important to help ensure that the medical need will eventually be met.”

The two companies will develop the products jointly through Phase II clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization.

Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase II studies.

Immune Design will be eligible to receive future milestone and royalty payments on any product developed from the collaboration; other financial terms of the agreement have not been disclosed.